[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.218.90. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1996

The Effects of Corticosteroids on Adenoviral Replication

Author Affiliations

From the Campbell Laboratory for Infectious Eye Diseases, Department of Ophthalmology, University of Pittsburgh (Pa) School of Medicine. The authors have no proprietary interest in the companies or products mentioned in this article.

Arch Ophthalmol. 1996;114(5):581-585. doi:10.1001/archopht.1996.01100130573014
Abstract

Objective:  To evaluate the effects of Pred Forte (prednisolone acetate; Allergan Pharmaceutical, Irvine, Calif) on the replication of different adenoviral serotypes in vitro and in the adenovirus type 5/New Zealand rabbit ocular model.

Methods:  The 50% inhibitory doses of Pred Forte and its components were determined for common ocular serotypes. The effects of continuous topical treatment with Pred Forte for 18 days were evaluated (eg, conjunctivitis, subepithelial immune infiltrates, and serial ocular viral titers) in the adenovirus 5/New Zealand rabbit ocular model.

Results:  Pred Forte and prednisolone acetate inhibited adenoviruses 1, 5, 8, and 19 in vitro. In vivo, 1% Pred Forte significantly reduced conjunctivitis (P=.04) and subepithelial infiltrates (P=.02), but enhanced viral replication (P=.01) on days 9 to 21 and increased the duration of viral shedding (P<.001).

Conclusions:  Despite demonstrated anti-inflammatory and anti-immune effects, prolonged treatment of acute adenoviral infections with topical Pred Forte is not recommended because of the enhanced risks of viral transmission and community epidemics.

References
1.
Tullo A.  The adenoviruses . In: Easty DL, ed. Virus Diseases of the Eye . Chicago, III: Year Book Medical Publishers; 1985:257-270.
2.
Laibson PR.  Ocular adenoviral infections . Int Ophthalmol Clin . 1984;24:49-64.
3.
Arffa RC. Grayson's Diseases of the Cornea . 3rd ed. Boston, Mass: Mosby-Year Book; 1991:277-280.
4.
Kaufman HE, Rayfield RC.  Viral conjunctivitis and keratitis . In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea . New York, NY: Churchill Livingstone; 1988:325-327.
5.
Gordon JS.  Adenoviruses and other nonherpetic viral diseases . In: Smolin G, Thoft RA, eds. The Cornea . 3rd ed. Boston, Mass: Little Brown & Co; 1994:215-227.
6.
Gordon YJ, Romanowski E, Araullo-Cruz T, et al.  Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic-GMP on clinical ocular adenoviral isolates is serotype dependent in vitro . Antiviral Res . 1991;16:11-16.Article
7.
Gordon YJ, Romanowski EG, Araullo-Cruz T.  Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model . Invest Ophthalmol Vis Sci . 1994;35:4135-4143.
8.
Gordon YJ, Romanowski E, Araullo-Cruz T, De Clerq E.  Pretreatment with topical 0.1% (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular replication model . Cornea . 1992;11:529-533.Article
9.
Gordon YJ, Romanowski E, Araullo-Cruz T.  An ocular model of adenovirus type 5 infection in the NZ rabbit . Invest Ophthalmol Vis Sci . 1992;33:574-580.
10.
Ward JB, Siojo LG, Waller SG.  A prospective masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis . Cornea . 1993;12:216-221.Article
11.
DeClercq E.  Therapeutic potential of HPMPC as an antiviral . Rev Med Virol . 1993;3:85-96.Article
12.
Pavan-Langston D, Dunkel EC.  Antiviral drugs . In: Handbook of Ocular Drug Therapy and Ocular Side Effects of Systemic Drugs . Boston, Mass: Little Brown & Co; 1991:158-181.
×